Asset profile
Lobeglitazone · Duvie
Small molecule
Evidence outlook · lead readout
NCT02002611 · Type 2 Diabetes Mellitus
The reported results come from study designs that frequently fail to replicate under controlled conditions — see the rationale below.
NCT02002611: Every participant received both lobeglitazone and warfarin, so there is no separate group showing what would have happened without lobeglitazone, and nobody was blinded to treatment. The measures collected were drug-level readings for a drug-interaction check, not a symptom or disease-based result, so this trial offers only limited evidence about lobeglitazone's own effects.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.